<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">V.F.Snegirev Archives of Obstetrics and Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">V.F.Snegirev Archives of Obstetrics and Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Архив акушерства и гинекологии им. В.Ф. Снегирева</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-8726</issn><issn publication-format="electronic">2687-1386</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">633449</article-id><article-id pub-id-type="doi">10.17816/aog633449</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original study articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="zh"><subject>Original study articles</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Alternative treatment strategies for bacterial vaginosis: the role of lactic acid in combating antibiotic resistance</article-title><trans-title-group xml:lang="ru"><trans-title>Альтернативные стратегии лечения бактериального вагиноза, включающие использование молочной кислоты, как потенциальное решение проблемы антибиотикорезистентности</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>包括乳酸在内的细菌性阴道病替代治疗策略： 抗生素耐药性问题的潜在解决方案</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5157-1888</contrib-id><contrib-id contrib-id-type="spin">6649-7776</contrib-id><name-alternatives><name xml:lang="en"><surname>Minakova</surname><given-names>Alena D.</given-names></name><name xml:lang="ru"><surname>Минакова</surname><given-names>Алена Дмитриевна</given-names></name><name xml:lang="zh"><surname>Minakova</surname><given-names>Alena D.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>
</p><p>
</p><p>
</p><p>
</p><p>Postgraduate Student</p>



</bio><bio xml:lang="ru"><p>
</p><p>
</p><p>
</p><p>
</p><p>аспирант</p>



</bio><bio xml:lang="zh"><p>Postgraduate Student</p></bio><email>alenami1205@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1540-5628</contrib-id><contrib-id contrib-id-type="spin">5688-1084</contrib-id><name-alternatives><name xml:lang="en"><surname>Dzhibladze</surname><given-names>Tea A.</given-names></name><name xml:lang="ru"><surname>Джибладзе</surname><given-names>Теа Амирановна</given-names></name><name xml:lang="zh"><surname>Dzhibladze</surname><given-names>Tea A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>
</p><p>
</p><p>
</p><p>
</p><p>MD, Dr. Sci. (Medicine), Professor</p>



</bio><bio xml:lang="ru"><p>
</p><p>
</p><p>
</p><p>
</p><p>д-р мед. наук, профессор</p>



</bio><bio xml:lang="zh"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><email>djiba@bk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8715-2020</contrib-id><contrib-id contrib-id-type="spin">2857-0309</contrib-id><name-alternatives><name xml:lang="en"><surname>Zuev</surname><given-names>Vladimir M.</given-names></name><name xml:lang="ru"><surname>Зуев</surname><given-names>Владимир Михайлович</given-names></name><name xml:lang="zh"><surname>Zuev</surname><given-names>Vladimir M.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>
</p><p>
</p><p>
</p><p>
</p><p>MD, Dr. Sci. (Medicine), Professor</p>



</bio><bio xml:lang="ru"><p>
</p><p>
</p><p>
</p><p>
</p><p>д-р мед. наук, профессор</p>



</bio><bio xml:lang="zh"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><email>vlzuev@bk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8547-6750</contrib-id><contrib-id contrib-id-type="spin">6858-5235</contrib-id><name-alternatives><name xml:lang="en"><surname>Khokhlova</surname><given-names>Irina D.</given-names></name><name xml:lang="ru"><surname>Хохлова</surname><given-names>Ирина Дмитриевна</given-names></name><name xml:lang="zh"><surname>Khokhlova</surname><given-names>Irina D.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>
</p><p>
</p><p>
</p><p>
</p><p>MD, Cand. Sci. (Medicine), Assistant Professor</p>



</bio><bio xml:lang="ru"><p>
</p><p>
</p><p>
</p><p>
</p><p>канд. мед. наук, доцент</p>



</bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Medicine), Assistant Professor</p></bio><email>irhohlova5@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет им. И.М. Сеченова</institution></aff><aff><institution xml:lang="zh">I.M. Sechenov First Moscow State Medical University</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-02-24" publication-format="electronic"><day>24</day><month>02</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-02-24" publication-format="electronic"><day>24</day><month>02</month><year>2025</year></pub-date><volume>12</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>84</fpage><lpage>91</lpage><history><date date-type="received" iso-8601-date="2024-06-15"><day>15</day><month>06</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-12-06"><day>06</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2025,</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2027-04-11"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://archivog.com/2313-8726/article/view/633449">https://archivog.com/2313-8726/article/view/633449</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND</bold>: Bacterial vaginosis is a common infectious non-inflammatory vaginal condition that increases susceptibility to sexually transmitted diseases, negatively impacts perinatal outcomes, and reduces overall quality of life. Considering the low long-term effectiveness of antibiotic therapy, the high recurrence rates, and the frequent side effects associated with its use, there is a growing need to explore alternative approaches for bacterial vaginosis treatment.</p> <p><bold>AIM</bold>: To evaluate the efficacy and tolerability of a two-step treatment approach for bacterial vaginosis, which includes clindamycin or dequalinium chloride and lactic acid, in women of reproductive age.</p> <p><bold>MATERIALS AND METHODS</bold>: An open-label randomized clinical trial was conducted, including 93 women aged 18–45 years diagnosed with bacterial vaginosis according to Amsel’s criteria. Participants were randomly assigned to three groups: 31 women in the first group received lactic acid monotherapy, 31 in the second group received a combination of clindamycin and lactic acid, and 31 in the third group were treated with dequalinium chloride and lactic acid. Treatment efficacy was assessed after 14 days using Amsel’s criteria. Three months post-treatment, patient-reported symptoms and vaginal pH levels were evaluated.</p> <p><bold>RESULTS</bold>: Two weeks post-treatment, bacterial vaginosis symptoms persisted in 3 (9.7%) patients from the first group and in 1 (3.2%) patient from the second group. A positive trend in vaginal pH normalization was observed in all groups both at the two-week and three-month follow-ups. At the three-month follow-up, vaginal discharge complaints persisted in one patient from the first group, one from the second, and two from the third. The efficacy of lactic acid monotherapy at day 14 was 90.3%, increasing to 96.4% at three months. The two-step therapy combining clindamycin and lactic acid demonstrated an efficacy of 96.8% and 96.7%, respectively. The two-step therapy with dequalinium chloride and lactic acid demonstrated 100% efficacy after 14 days and 93.3% at the three-month follow-up. A case of vulvovaginal candidiasis was reported in the second group three months after treatment.</p> <p><bold>CONCLUSION</bold>: This study demonstrated the sustained high efficacy of the two-step treatment approach in both short-term and long-term perspectives. Whereas monotherapy initially showed lower efficacy, its long-term outcomes became comparable, highlighting the importance of lactic acid in combination therapy.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование</bold>. Бактериальный вагиноз является распространённым инфекционным невоспалительным заболеванием влагалища, которое повышает вероятность заражения инфекциями, передающимися половым путём, оказывая негативное влияние на перинатальные исходы и снижая качество жизни в целом. С учётом низкой эффективности антибактериальной терапии в долгосрочной перспективе, а также высокой частоты рецидивов и побочных эффектов, связанных с применением антибиотиков, возникает необходимость в поиске альтернативных подходов к лечению бактериального вагиноза.</p> <p><bold>Цель</bold>. Оценить эффективность и переносимость комплексного двухэтапного метода лечения бактериального вагиноза, включающего клиндамицин или деквалиния хлорид и молочную кислоту, у женщин репродуктивного возраста.</p> <p><bold>Материалы и методы</bold>. Проведено открытое рандомизированное клиническое исследование, в котором приняли участие 93 женщины 18–45 лет с диагнозом «бактериальный вагиноз», подтверждённым по критериям Амселя. Пациентки были случайным образом распределены на три группы: у 31 женщины из первой группы использовали молочную кислоту; у 31 женщины из второй группы — комбинацию клиндамицина и молочной кислоты; у 31 женщины из третьей группы — деквалиния хлорид с молочной кислотой. Эффективность лечения оценивали через 14 дней с использованием критериев Амселя. Спустя три месяца после завершения лечения оценивали жалобы и измеряли pH влагалищного отделяемого.</p> <p><bold>Результаты</bold>. В ходе исследования отмечено, что через две недели после завершения лечения симптомы бактериального вагиноза продолжали сохраняться у 3 (9,7%) пациенток в первой группе, у 1 (3,2%) — во второй группе. Положительная динамика изменения pH вагинального отделяемого наблюдалась во всех группах как через две недели, так и через три месяца после окончания лечения. Спустя три месяца после окончания лечения жалобы на выделения из половых путей сохранились у одной женщины из первой группы, у одной — из второй, у двух — из третьей. Эффективность лечения c использованием молочной кислоты на 14-й день составила 90,3%, через три месяца — 96,4%. Двухэтапная терапия с применением клиндамицина и молочной кислоты показала эффективность 96,8% и 96,7% соответственно. Лечение с использованием деквалиния хлорида и молочной кислоты продемонстрировало 100,0% эффективность через 14 дней и 93,3% через три месяца. Во второй группе был зафиксирован случай вульвовагинального кандидоза через три месяца.</p> <p><bold>Заключение</bold>. Проведённое исследование подтвердило высокую эффективность двухэтапного метода лечения как в краткосрочной, так и в долгосрочной перспективе. Несмотря на то что монотерапия изначально показала меньшую эффективность, её результаты в дальнейшем стали сравнимыми, что подчёркивает важность использования молочной кислоты в комплексной терапии.</p></trans-abstract><trans-abstract xml:lang="zh"><p>背景。细菌性阴道病（BV, Bacterial Vaginosis）是一种常见的非炎症性阴道感染，可增加性传播感染的风险，对围产期结局产生不良影响，并降低整体生活质量。由于抗菌治疗在长期管理中的效果有限，并且抗生素治疗相关的复发率和不良反应较高，因此迫切需要寻找BV的替代治疗方法。</p> <p>目的。 评估采用克林霉素或地喹氯铵联合乳酸的两阶段综合治疗方案在育龄期女性中的疗效和耐受性。</p> <p>材料与方法。本研究为一项开放性随机临床试验，共纳入93名18-45岁、符合Amsel标准确诊的BV女性患者。患者被随机分为三组：第一组（n=31）接受乳酸治疗；第二组（n=31）接受克林霉素联合乳酸治疗；第三组（n=31）接受地喹氯铵联合乳酸治疗。在治疗结束后14天，依据Amsel标准评估治疗效果。在治疗后三个月评估患者症状并测量阴道分泌物pH值。</p> <p>结果。研究显示，在治疗结束两周后，细菌性阴道病症状仍持续存在于第一组3例（9.7%）患者，第二组1例（3.2%）患者。阴道分泌物pH值在所有研究组中均呈现积极变化，且该变化在治疗结束两周及三个月后仍保持稳定。三个月后，第一组1例患者、第二组1例患者、第三组2例患者仍报告阴道分泌物异常。乳酸单一治疗的有效率在治疗后14天为90.3%，三个月后为96.4%。克林霉素联合乳酸的两阶段治疗有效率分别为96.8%（14天）和96.7%（三个月）。地喹氯铵联合乳酸治疗的有效率在14天时为100.0%，三个月后为93.3%。此外，在第二组随访中发现1例治疗后三个月出现外阴阴道念珠菌病的病例。</p> <p>结论。本研究证实了两阶段治疗方案在短期及长期均具有较高的疗效。尽管乳酸单一治疗的初始效果较低，但其远期疗效与其他方案相当，突出了乳酸在细菌性阴道病综合治疗中的重要性。</p></trans-abstract><kwd-group xml:lang="en"><kwd>bacterial vaginosis</kwd><kwd>lactic acid</kwd><kwd>clindamycin</kwd><kwd>dequalinium chloride</kwd><kwd>two-step treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>бактериальный вагиноз</kwd><kwd>молочная кислота</kwd><kwd>клиндамицин</kwd><kwd>деквалиния хлорид</kwd><kwd>двухэтапное лечение</kwd></kwd-group><kwd-group xml:lang="zh"><kwd>细菌性阴道病</kwd><kwd>乳酸</kwd><kwd>克林霉素</kwd><kwd>地喹氯铵</kwd><kwd>两阶段治疗</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Peebles K, Velloza J, Balkus JE, et al. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis. 2019;46(5):304–311. doi: 10.1097/OLQ.0000000000000972</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Abou Chacra L, Ly C, Hammoud A, et al. Relationship between bacterial vaginosis and sexually transmitted infections: coincidence, consequence or co-transmission? Microorganisms. 2023;11(10):2470. doi: 10.3390/microorganisms11102470</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Mohanty T, Doke PP, Khuroo SR. Effect of bacterial vaginosis on preterm birth: a meta-analysis. Arch Gynecol Obstet. 2023;308(4):1247–1255. doi: 10.1007/s00404-022-06817-5</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Kenfack-Zanguim J, Kenmoe S, Bowo-Ngandji A, et al. Systematic review and meta-analysis of maternal and fetal outcomes among pregnant women with bacterial vaginosis. Eur J Obstet Gynecol Reprod Biol. 2023; 289:9–18. doi: 10.1016/j.ejogrb.2023.08.013</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Vieira-Baptista P, Stockdale CK, Sobel J. International society for the study of vulvovaginal disease recommendations for the diagnosis and treatment of vaginitis. Lisbon: Admedic; 2023. Р. 73–75. doi: 10.59153/adm.rdtv.001</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478–1486. doi: 10.1086/503780</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>O’Hanlon DE, Moench TR, Cone RA. Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoS One. 2013;8(11):e80074. doi: 10.1371/journal.pone.0080074</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>O’Hanlon DE, Moench TR, Cone RA. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect Dis. 2011; 11:200. doi: 10.1186/1471-2334-11-200</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Kira EF, Korshakova NYu. Open randomized placebo-controlled study of the effectiveness and safety of monotherapy of bacterial vaginosis by vaginal application of lactic acid. Obstetrics and Gynecology. 2018;(5):96–100. doi: 10.18565/aig.2018.5.96-101 EDN: XOSMXZ</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Ross JDC, Brittain C, Anstey Watkins J, et al. Intravaginal lactic acid gel versus oral metronidazole for treating women with recurrent bacterial vaginosis: the VITA randomised controlled trial. BMC Womens Health. 2023;23(1):241. doi: 10.1186/s12905-023-02303-5</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Paavonen J, Mangioni C, Martin MA, Wajszczuk CP. Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet Gynecol. 2000;96(2):256–260. doi: 10.1016/s0029-7844(00)00902-9</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Mendling W, Weissenbacher ER, Gerber S, et al. Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review. Arch Gynecol Obstet. 2016;293(3):469–484. doi: 10.1007/s00404-015-3914-8</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Gaspar C, Rolo J, Cerca N, et al. Dequalinium chloride effectively disrupts bacterial vaginosis (BV) Gardnerella spp. biofilms. Pathogens. 2021;10(3):261. doi: 10.3390/pathogens10030261</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Antoni Vives J, Cancelo MJ, Losada MA, Domenech A. Dequalinium chloride use in adult Spanish women with bacterial vaginosis: an observational study. J Obstet Gynaecol. 2022;42(1):103–109. doi: 10.1080/01443615.2020.1867966</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Weissenbacher ER, Donders G, Unzeitig V, et al. A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest. 2012;73(1):8–15. doi: 10.1159/000332398</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Raba G, Durkech A, Malík T, et al. Efficacy of dequalinium chloride vs metronidazole for the treatment of bacterial vaginosis: a randomized clinical trial. JAMA Netw Open. 2024;7(5):e248661. doi: 10.1001/jamanetworkopen.2024.8661</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Bhujel R, Mishra SK, Yadav SK, et al. Comparative study of Amsel’s criteria and Nugent scoring for diagnosis of bacterial vaginosis in a tertiary care hospital, Nepal. BMC Infect Dis. 2021;21(1):825. doi: 10.1186/s12879-021-06562-1</mixed-citation></ref></ref-list></back></article>
